Yahoo Finance • 4 months ago
Perrigo Company plc's (NYSE:PRGO) investors are due to receive a payment of $0.276 per share on 17th of September. This makes the dividend yield 4.0%, which will augment investor returns quite nicely. Check out our latest analysis for Per... Full story
Yahoo Finance • 8 months ago
Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to €275 Million, Consisting of €190 Million in Cash Upfront and up to €85 Mill... Full story
Yahoo Finance • 10 months ago
Perrigo Company plc (NYSE:PRGO) Q4 2023 Earnings Call Transcript February 27, 2024 Perrigo Company plc beats earnings expectations. Reported EPS is $0.86, expectations were $0.83. PRGO isn't one of the 30 most popular stocks among hedge f... Full story
Yahoo Finance • 10 months ago
WASHINGTON (AP) — The first over-the-counter birth control pill will be available in U.S. stores later this month, allowing American women and teens to purchase contraceptive medication as easily as they buy aspirin. Manufacturer Perrigo... Full story
Yahoo Finance • last year
Insight into the Investment Firm's Latest 13F Filings for Q3 2023 Barrow, Hanley, Mewhinney & Strauss (Trades, Portfolio), a distinguished Dallas-based investment firm, is known for its conservative value investment philosophy. The firm,... Full story
Yahoo Finance • last year
Perrigo Co PLC (NYSE:PRGO) reports a 2.2% increase in net sales for Q3 2023, amounting to $1.1 billion. The company's gross margin and operating margin expanded year-over-year and sequentially. Adjusted diluted EPS increased by 14.3% compa... Full story
Yahoo Finance • last year
Perrigo Company plc (NYSE: PRGO) shares are trading higher after the FDA approved the company's Opill, a progestin-only daily oral contraceptive for over-the-counter (OTC) use for all ages. Opill is the first-ever birth control pill avail... Full story
Yahoo Finance • last year
The Food and Drug Administration approved the first over-the-counter birth-control pill, significantly expanding access to contraception among women across the U.S.... Full story
Yahoo Finance • last year
DUBLIN, July 13, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration (FDA) approved Opill®, a progestin-only daily oral contra... Full story
Yahoo Finance • 2 years ago
DUBLIN, May 16, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for Nicotine Coated Mi... Full story
Yahoo Finance • 2 years ago
Advisers to the Food and Drug Administration recommended making an oral contraceptive available without a prescription for the first time, potentially widening access to birth control for women across the country. The panel of FDA advisers... Full story
Yahoo Finance • 2 years ago
Stolkholm’s Best Kept Skincare Secret Is The Perfect Gift For Giving SENSITIVE BALANCE STARTER KIT - SRP: $95 USD Say goodbye to redness while you soothe, nourish and strengthen sensitive skin with this starter set. Includes: Sensitive Ba... Full story
Yahoo Finance • 2 years ago
DUBLIN, Aug. 2, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.26 per share, payable on Septe... Full story
Yahoo Finance • 2 years ago
Sixty-two years after the US was the first country to offer women hormonal birth control—commonly known as “the pill”—the 12 million American women who take it might finally be able to get it without prescription. Today, HRA Pharma, a Fren... Full story
Yahoo Finance • 3 years ago
Head of Growth at Kendamil Dylan McMahon joins Yahoo Finance Live to discuss the company working alongside the FDA to ship baby formula to the U.S., the stranglehold domestic baby formula producers have on the U.S. market, and the outlook... Full story